Results 11 to 20 of about 12,380 (194)

Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST‐Elevation Myocardial Infarction [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundEarly withdrawal of recommended antiplatelet treatment with clopidogrel adversely affects prognosis following percutaneous coronary interventions. Optimal antiplatelet treatment is essential following ST‐segment elevation myocardial infarction (
Konstantinos C. Koskinas, Thomas Zanchin, Roland Klingenberg, Baris Gencer, Fabrice Temperli, Andreas Baumbach, Marco Roffi, Aris Moschovitis, Oliver Muller, David Tüller, Stefan Stortecky, Francois Mach, Thomas F. Lüscher, Christian M. Matter, Thomas Pilgrim, Dik Heg, Stephan Windecker, Lorenz Räber   +17 more
doaj   +2 more sources

Eversion endarterectomy under full prasugrel treatment

SAGE Open Medical Case Reports, 2017
The third-generation thienopyridine prasugrel has much stronger antiplatelet effect compared to other current antiplatelet inhibitors and exhibits practically zero resistance in healthy people.
Thomas Kotsis, Panagitsa Christoforou, Nikolaos Asaloumidis, Erifyli Argyra   +3 more
doaj   +3 more sources

Prasugrel for the treatment of patients with acute coronary syndrome

Vascular Health and Risk Management, 2009
Filippo Marzot, Vittorio PengoClinical Cardiology, Thrombosis Centre, University of Padua, ItalyAbstract: Prasugrel (CS-747, LY640315) is a novel member of the thienopyridine class of oral anti-platelet agents (also including ticlopidine and clopidogrel).
Filippo Marzot, Vittorio Pengo
doaj   +1 more source

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel

Thrombosis Journal, 2018
Background Although prasugrel exerts stronger antiplatelet effects compared with clopidogrel, the factors affecting platelet reactivity under prasugrel have not been fully determined. This study aimed to find the novel mechanistic differences between two
Satoshi Niijima, Tsukasa Ohmori, Kazuomi Kario   +2 more
doaj   +2 more sources

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel

Clinical Medicine Insights: Cardiology, 2016
Objectives A growing body of clinical and laboratory evidence indicates that inflammation plays a crucial role in atherosclerosis. In the present study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP ...
Shokoufeh Hajsadeghi, Mandana Chitsazan, Mitra Chitsazan, Negar Salehi, Ahmad Amin, Arash Amin Bidokhti, Nima Babaali, Armin Bordbar, Maral Hejrati, Samar Moghadami   +9 more
doaj   +2 more sources

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Vascular Health and Risk Management, 2009
Nicholas B Norgard,1 Mazen Abu-Fadel21University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA; 2University of Oklahoma Health Sciences Center, Cardiovascular Section, Oklahoma City, OK, USAAbstract: Antiplatelet agents are
Nicholas B Norgard, Mazen Abu-Fadel
doaj   +1 more source

Prasugrel-related hepatotoxicity [PDF]

, 2022
Prasugrel, daha güçlü ve daha hızlı antitrombotik aktivasyonu nedeniyle, akut koroner sendrom sırasında perkütan koroner girişim uygulanan hastalarda tekrarlayan koroner tromboz riskini azaltmak için genellikle Klopidogrel'e tercih edilir.
Bektaşoğlu, Gökhan, Yurtdaş, Mustafa, Doğan, Zeki   +2 more
core   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Platelet Blockage: Prasugrel versus Ticagrelor: Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5

Journal of the Practice of Cardiovascular Sciences, 2019
The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 trial randomized patients with acute coronary syndrome for whom invasive treatment was planned to ticagrelor versus prasugrel.
Venkatakrishnan Ramakumar
doaj   +1 more source

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions

Indian Heart Journal, 2018
Background: Although conventional 60 mg of prasugrel allows for rapid and potent platelet inhibition within 30 min after loading dose, the efficacy and safety of lower doses of prasugrel in Indian patients has not yet been investigated.
Priti Kumari, Bhanwar Lal Ranwa
doaj   +1 more source